<DOC>
	<DOCNO>NCT02916147</DOCNO>
	<brief_summary>This study aim observe compare change alarmins high mobility group nucleosome-binding protein-1 ( HMGN1 ) , high mobility group proteins b1 ( HMGb1 ) , Interleukin ( IL ) -33 soluble receptor include soluble toll like receptor 4 ( sTLR4 ) soluble ST2 ( sST2 ) pulmonary lobectomy cancer patient receive volatile anesthesia intravenous anesthesia one-lung ventilation ( OLV ) . By , study preliminarily evaluate correlation alarmins prognosis well effect inhalational intravenous anesthesia prognosis surgical patient .</brief_summary>
	<brief_title>Effect Different Anesthetics Change Alarmins Lung Cancer Patients Receiving Pulmonary Lobectomy</brief_title>
	<detailed_description>During pulmonary lobectomy , result OLV surgical operation , patient suffer alveolar systemic inflammatory response . Alarmin endogenous peptide release white blood cell epithelial cell body undergo danger signal stimulation enhance immune response double effect tumor . Some alarmins soluble receptor HMGN1 , HMGb1 , IL-33 soluble receptor include sTLR4 sST2 use biomarkers tumor progression . Previous study show sevoflurane anesthesia reduce level inflammatory cytokine bronchoalveolar lavage fluid . Meanwhile , late retrospective study indicate mortality cancer patient receive volatile anesthesia significantly higher intravenous anesthesia . At stage , study aim investigate change alarmins broncho-alveoli serum OLV lung surgery possible effect different anesthetic . Therefore , investigator plan enroll 40 patient lung cancer receive pulmonary lobectomy . Patients randomly divide sevoflurane volatile anesthesia group propofol intravenous anesthesia group ( n=20 ) . Perioperative serum bronchoalveolar lavage ventilate lung obtain , use ELISA method , assay compare change alarmins HMGN1 , HMGb1 , IL-33 soluble receptor include sTLR4 sST2 two group . All patient follow 12 month . The correlation alarmins prognosis well effect volatile intravenous anesthesia prognosis patient preliminarily evaluate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>American society Anesthesiology ( ASA ) status III pathological diagnosis lung cancer surgery receive pulmonary lobectomy normal lung function without heart failure ( NYHA &gt; 2 ) , obstructive restrictive lung disease history malignancy tumor body mass index ( Body mass , index , BMI ) &lt; 35kg/m2 severe coagulopathy severe systemic pulmonary infection participate clinical trial persistent smoke history immunosuppressive drug use 6 week operation receive total pneumonectomy failure complete treatment followup severe adverse drug reaction severe postoperative complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>